A scalable and eco-friendly total synthesis of PARP inhibitor.
Combinational therapy has become a widely adopted strategy in cancer treatment, offering benefits such as reduced dosages, decreased toxicity, and prevention of drug resistance.
This review explains the role of molecular imaging (nano)probes in medical diagnostics, highlights development challenges, and explores future improvements for clinical use.
6Yn-Pro is a cell-permeable proprobe successfully undergoing metabolic conversion into 6Yn-NAD+ for subsequent intracellular labelling of ADP-ribosylated proteins.
Novel quinazoline-based ATR inhibitor (11) developed via scaffold hopping shows strong anticancer activity against ATM proficient/deficient cancer, low toxicity in non-cancerous cells, and shows potential as a preclinical candidate.